Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.64 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.60 |
| ▸ | CA1 | P00915 | 4/20 | 0.58 |
| ▸ | CA2 | P00918 | 4/20 | 0.58 |
| ▸ | CA9 | Q16790 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6013937 | 0.87 | PTGS2 (0.80) | PTGS2PTGS1PDPK1CHRNA7CA1 | |
| SCHEMBL6013905 | 0.86 | PTGS2 (0.78) | PTGS2PTGS1PDPK1CHRNA7CA1 | |
| SCHEMBL213633 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CHRNA7CA1 | |
| SCHEMBL27457917 | 0.86 | PTGS2 (0.78) | PTGS2PTGS1PDPK1CHRNA7CA1 | |
| SCHEMBL6307479 | 0.83 | PTGS2 (0.77) | PTGS2PTGS1PDPK1CHRNA7CA1 | |
| SCHEMBL6315704 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CHRNA7CA1 | |
| SCHEMBL24393627 | 0.82 | PTGS2 (0.72) | PTGS2PTGS1PDPK1CHRNA7CA1 | |
| SCHEMBL6344415 | 0.81 | PTGS2 (0.73) | PTGS2PTGS1PDPK1CHRNA7SMN1; SMN2 | |
| SCHEMBL6352494 | 0.81 | PTGS2 (0.74) | PTGS2PTGS1PDPK1CHRNA7CA1 | |
| SCHEMBL6501484 | 0.81 | PTGS2 (0.74) | PTGS2PTGS1CHRNA7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190038756-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, SILK FIBROIN, AND A GELLING AGENT AND USES THEREOF | COCOON BIOTECH INC. | 2019-02-07 | — | — | US | disclosed |
| US-9315483-B2 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038756-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, SILK FIBROIN, AND A GELLING AGENT AND USES THEREOF | MB, PTGES, PTGS1 | PTGS2 12/4885PTGS1 3/4885PDPK1 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.